Methods of using ox40 ligand encoding polynucleotides

Abstract

The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide. Also provided is a method for activating T cells or increasing the number of NK cells in a subject in need thereof.

1 .- 17 . (canceled) 
     
     
         18 . A method for treating a carcinoma in a subject, the method comprising administering to the subject a lipid nanoparticle (LNP) encapsulated messenger RNA (mRNA) encoding a human OX40L polypeptide, thereby treating the carcinoma in the subject. 
     
     
         19 . The method of  claim 18 , wherein the OX40L polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 1. 
     
     
         20 . The method of  claim 18 , wherein the mRNA comprises an open reading frame (ORF), and wherein the ORF comprises a nucleotide sequence at least 90% identical to SEQ ID NO: 4. 
     
     
         21 . The method of  claim 20 , wherein the ORF comprises the nucleotide sequence as set forth in SEQ ID NO: 4. 
     
     
         22 . The method of  claim 18 , wherein the mRNA is fully modified with chemically-modified nucleotides. 
     
     
         23 . The method of  claim 22 , wherein the chemically-modified nucleotides are N1-methylpseudouridines (m1ψ). 
     
     
         24 . The method of  claim 22 , wherein the mRNA is fully modified with 5-methylcytosine or is fully modified with m1ψ and 5-methylcytosine. 
     
     
         25 . The method of  claim 18 , comprising administering a second mRNA encoding a second polypeptide in combination with the LNP. 
     
     
         26 . The method of  claim 25 , wherein the LNP comprises the second mRNA. 
     
     
         27 . The method of  claim 18 , comprising administering an effective amount of an immune checkpoint inhibitor in combination with the LNP. 
     
     
         28 . The method of  claim 27 , wherein the immune checkpoint inhibitor is a PD-1 antagonist, a PD-L1 antagonist or a CTLA-4 antagonist. 
     
     
         29 . The method of  claim 28 , wherein the PD-1 antagonist is an antibody or antigen binding portion thereof that specifically binds to PD-1, wherein the PD-L1 antagonist is an antibody or antigen binding portion thereof that specifically binds to PD-L1, and wherein the CTLA-4 antagonist is an antibody or antigen binding portion thereof that specifically binds to CTLA-4. 
     
     
         30 . The method of  claim 29 , wherein the PD-1 antagonist is selected from the group consisting of nivolumab, pembrolizumab, and pidilizumab, wherein the PD-L1 antagonist is selected from the group consisting of durvalumab, avelumab, and atezolizumab, and wherein the CTLA-4 antagonist is selected from the group consisting of ipilimumab and tremelimumab. 
     
     
         31 . The method of  claim 18 , wherein the mRNA comprises at least one microRNA-122 (miR-122) binding site. 
     
     
         32 . The method of  claim 31 , wherein the miR-122 binding site is a miR-122-3p binding site or a miR-122-5p binding site. 
     
     
         33 . The method of  claim 32 , wherein the miR-122-5p binding site comprises the nucleotide sequence as set forth in SEQ ID NO: 26. 
     
     
         34 . The method of  claim 31 , wherein the mRNA comprises a 3′ untranslated region (UTR) and a 5′ UTR, and wherein the miR-122 binding site is located within the 3′ UTR of the mRNA, the 5′ UTR of the mRNA, or a combination thereof. 
     
     
         35 . The method of  claim 34 , wherein the 3′ UTR comprises the nucleotide sequence as set forth in SEQ ID NO: 63. 
     
     
         36 . The method of  claim 18 , wherein the mRNA comprises a nucleotide sequence at least 90% identical to SEQ ID NO: 65 or wherein the mRNA comprises the nucleotide sequence as set forth in SEQ ID NO: 65. 
     
     
         37 . The method of  claim 18 , wherein the LNP is administered intratumorally.